PuSH - Publikationsserver des Helmholtz Zentrums München

Phillip, M.* ; Achenbach, P. ; Addala, A.* ; Albanese-O'Neill, A.* ; Battelino, T.* ; Bell, K.J.* ; Besser, R.E.J.* ; Bonifacio, E. ; Colhoun, H.M.* ; Couper, J.J.* ; Craig, M.E.* ; Danne, T.* ; de Beaufort, C.* ; Dovc, K.* ; Driscoll, K.A.* ; Dutta, S.* ; Ebekozien, O.* ; Larsson, H.E.* ; Feiten, D.J.* ; Frohnert, B.I.* ; Gabbay, R.A.* ; Gallagher, M.P.* ; Greenbaum, C.J.* ; Griffin, K.J.* ; Hagopian, W.* ; Haller, M.J.* ; Hendrieckx, C.* ; Hendriks, E.* ; Holt, R.I.G.* ; Hughes, L.* ; Ismail, H.M.* ; Jacobsen, L.M.* ; Johnson, S.B.* ; Kolb, L.E.* ; Kordonouri, O.* ; Lange, K.* ; Lash, R.W.* ; Lernmark, Å.* ; Libman, I.M.* ; Lundgren, M.* ; Maahs, D.M.* ; Marcovecchio, M.L.* ; Mathieu, C.* ; Miller, K.M.* ; O'Donnell, H.K.* ; Oron, T.* ; Patil, S.P.* ; Pop-Busui, R.* ; Rewers, M.J.* ; Rich, S.S.* ; Schatz, D.A.* ; Schulman-Rosenbaum, R.* ; Simmons, K.M.* ; Sims, E.K.* ; Skyler, J.S.* ; Smith, L.B.* ; Speake, C.* ; Steck, A.K.* ; Thomas, N.P.B.* ; Tonyushkina, K.N.* ; Veijola, R.* ; Wentworth, J.M.* ; Wherrett, D.K.* ; Wood, J.R.* ; Ziegler, A.-G. ; Dimeglio, L.A.*

Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes.

Diabetologia, DOI: 10.1007/s00125-024-06205-5 (2024)
Verlagsversion DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Given the proven benefits of screening to reduce diabetic ketoacidosis (DKA) likelihood at the time of stage 3 type 1 diabetes diagnosis, and emerging availability of therapy to delay disease progression, type 1 diabetes screening programmes are being increasingly emphasised. Once broadly implemented, screening initiatives will identify significant numbers of islet autoantibody-positive (IAb+) children and adults who are at risk of (confirmed single IAb+) or living with (multiple IAb+) early-stage (stage 1 and stage 2) type 1 diabetes. These individuals will need monitoring for disease progression; much of this care will happen in non-specialised settings. To inform this monitoring, JDRF in conjunction with international experts and societies developed consensus guidance. Broad advice from this guidance includes the following: (1) partnerships should be fostered between endocrinologists and primary-care providers to care for people who are IAb+; (2) when people who are IAb+ are initially identified there is a need for confirmation using a second sample; (3) single IAb+ individuals are at lower risk of progression than multiple IAb+ individuals; (4) individuals with early-stage type 1 diabetes should have periodic medical monitoring, including regular assessments of glucose levels, regular education about symptoms of diabetes and DKA, and psychosocial support; (5) interested people with stage 2 type 1 diabetes should be offered trial participation or approved therapies; and (6) all health professionals involved in monitoring and care of individuals with type 1 diabetes have a responsibility to provide education. The guidance also emphasises significant unmet needs for further research on early-stage type 1 diabetes to increase the rigour of future recommendations and inform clinical care.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Autoantibodies ; Glucose Monitoring ; Prevention ; Type 1 Diabetes
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Zeitschrift Diabetologia
Verlag Springer
Verlagsort Berlin ; Heidelberg [u.a.]
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research Type 1 (IDF)
Institute for Pancreatic Beta Cell Research (IPI)